The differences between the first preferred biological dmard and the drug survival in geriatric and younger adult population with rheumatoid arthritis and psoriatic arthritis: Treasure real-life data

Gönüllü, E.Kalyoncu, U.Yağız, BurcuAteş, A.Küçükşahin, O.Bilge, S. YaşarKanitez, N. A.Çınar, M.Ersözlü, D.Mercan, R.Akar, S.Kaşifoğlu, T.Coşkun, B. NejdetKoca, S. S.Bilgin, E.Yazısız, V.Dalkılıç, EdizYılmaz, R.Kimyon, G.Türk, S. M.Erden, A.Beş, C.Emmungil, H.Pehlivan, YavuzErtenli, A. I.Kiraz, S.TReasure2024-11-282024-11-282022-06-010003-4967https://doi.org/10.1136/annrheumdis-2022-eular.2721https://ard.bmj.com/content/81/Suppl_1/1304.1https://hdl.handle.net/11452/48648Bu çalışma, 01-04, Haziran 2022 tarihlerinde Location Copenhagen[Danimarka]’da düzenlenen Annual European Congress of Rheumatology (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineRheumatologyThe differences between the first preferred biological dmard and the drug survival in geriatric and younger adult population with rheumatoid arthritis and psoriatic arthritis: Treasure real-life dataMeeting Abstract000850279005213130413048110.1136/annrheumdis-2022-eular.27211468-2060